<!doctype html><html><head><meta charset=utf-8><title>Hip fracture risk was reduced by 4 times when Vitamin D was added to SERMS</title>
<link rel=stylesheet href="/css/main.css?v=1748177521"><link rel=stylesheet href="/css/pagination.css?v=1748177521"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src=https://unpkg.com/lunr/lunr.js></script><script src=https://cdn.jsdelivr.net/npm/pako@2.1.0/dist/pako.min.js></script><script src="/js/search.js?v=1748177521"></script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><h1>Hip fracture risk was reduced by 4 times when Vitamin D was added to SERMS</h1><time>January 22, 2024</time><nav id=TableOfContents><ul><li><ul><li><ul><li><a href=#study-selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-agent-can-prevent-fracture-better-than-serms-treatment>Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:</a></li></ul></li></ul></li></ul></nav><hr><h4 id=study-selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-agent-can-prevent-fracture-better-than-serms-treatment>Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:</h4><p><strong>based on the National Health Claims Database 2017-2019</strong></p><p>Osteoporos Int 2024 Jan 19. <a href=https://doi.org/10.1007/s00198-024-07022-7>doi: 10.1007/s00198-024-07022-7</a> <a href="https://www.deepdyve.com/lp/springer-journals/selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-FCTILqFMaH?key=springer%20">Can be viewed at DeepDyve 1 month free trial</a></p><p>Seong-Eun Byun 1, Hasung Kim 2, Seung Yun Lee 2, Sang-Min Kim 3</p><p><strong>4X reduction in hip fractures in those who happened to be prescribed<br>to take some amount of Vitamin D in addition to SERMS</strong></p><img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/png/hip-d.png alt=image width=600><p>With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.</p><p>Purpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.</p><p>Methods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.</p><p>Results: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio <span>[HR]</span>, 0.77; 95% confidence interval <span>[CI]</span>, 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group.</p><p>Analysis for specific fractures showed a <strong>lower hazard of hip fracture in the SERM + VitD group (HR, 0.25</strong> ; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.</p><p>Conclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.</p><h5 id=26-references>26 References</h5><ol><li><p>Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed</p></li><li><p>Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. <a href=https://doi.org/10.1007/s40980-020-00061-8>https://doi.org/10.1007/s40980-020-00061-8</a> - DOI - PubMed - PMC</p></li><li><p>Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed</p></li><li><p>Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. <a href=https://doi.org/10.1016/j.afos.2020.11.007>https://doi.org/10.1016/j.afos.2020.11.007</a> - DOI - PubMed - PMC</p></li><li><p>Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. <a href=https://doi.org/10.1097/MCO>https://doi.org/10.1097/MCO</a> - DOI - PubMed - PMC</p></li><li><p>Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. <a href=https://doi.org/10.1007/s00198-017-3955-x>https://doi.org/10.1007/s00198-017-3955-x</a> - DOI - PubMed</p></li><li><p>Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. <a href=https://doi.org/10.1007/s00198-011-1868-7>https://doi.org/10.1007/s00198-011-1868-7</a> - DOI - PubMed - PMC</p></li><li><p>Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed</p></li><li><p>Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. <a href=https://doi.org/10.3349/ymj.2019.60.10.969>https://doi.org/10.3349/ymj.2019.60.10.969</a></p></li><li><p>Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52</p></li><li><p>Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. <a href=https://doi.org/10.1359/jbmr.2000.15.4.721>https://doi.org/10.1359/jbmr.2000.15.4.721</a> - DOI - PubMed</p></li><li><p>Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed</p></li><li><p>Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed</p></li><li><p>Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645</p></li><li><p>Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. <a href=https://doi.org/10.2147/CLEP.S164112>https://doi.org/10.2147/CLEP.S164112</a> - DOI - PubMed - PMC</p></li><li><p>Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed</p></li><li><p>Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed</p></li><li><p>LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. <a href=https://doi.org/10.1056/nejmoa2202106>https://doi.org/10.1056/nejmoa2202106</a> - DOI - PubMed - PMC</p></li><li><p>Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. <a href=https://doi.org/10.1016/j.maturitas.2020.06.016>https://doi.org/10.1016/j.maturitas.2020.06.016</a> - DOI - PubMed</p></li><li><p>Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. <a href=https://doi.org/10.1097/MD.0000000000011032>https://doi.org/10.1097/MD.0000000000011032</a> - DOI - PubMed</p></li><li><p>Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. <a href=https://doi.org/10.4162/nrp.2019.13.2.115>https://doi.org/10.4162/nrp.2019.13.2.115</a></p></li><li><p>Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed</p></li><li><p>Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. <a href=https://doi.org/10.6118/jmm.19193>https://doi.org/10.6118/jmm.19193</a> - DOI - PubMed - PMC</p></li><li><p>Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC</p></li><li><p>Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC</p></li><li><p>Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. <a href=https://doi.org/10.1016/S2213-8587(21)00345-4>https://doi.org/10.1016/S2213-8587(21)00345-4</a> - DOI - PubMed</p></li></ol><pre style=background-color:#e0e0e0;white-space:pre-wrap>
<code class=language-text>
Markdown:
--------
{{&lt; toc &gt;}}

---

#### Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:

 **based on the National Health Claims Database 2017-2019** 

Osteoporos Int  2024 Jan 19. [doi: 10.1007/s00198-024-07022-7](https://doi.org/10.1007/s00198-024-07022-7) [Can be viewed at DeepDyve 1 month free trial](https://www.deepdyve.com/lp/springer-journals/selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-FCTILqFMaH?key=springer%20)

Seong-Eun Byun 1, Hasung Kim 2, Seung Yun Lee 2, Sang-Min Kim 3

 **4X reduction in hip fractures in those who happened to be prescribed   
to take some  amount of Vitamin D in addition to SERMS** 

&lt;img src=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/png/hip-d.png&quot; alt=&quot;image&quot; width=&quot;600&quot;&gt;

With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.

Purpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.

Methods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.

Results: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio &lt;span&gt;[HR]&lt;/span&gt;, 0.77; 95% confidence interval &lt;span&gt;[CI]&lt;/span&gt;, 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. 

Analysis for specific fractures showed a  **lower hazard of hip fracture in the SERM + VitD group (HR, 0.25** ; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.

Conclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.

##### 26 References

1. Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed

1. Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8 - DOI - PubMed - PMC

1. Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed

1. Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007 - DOI - PubMed - PMC

1. Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCO - DOI - PubMed - PMC

1. Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-x - DOI - PubMed

1. Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7 - DOI - PubMed - PMC

1. Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed

1. Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969

1. Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52

1. Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721 - DOI - PubMed

1. Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed

1. Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed

1. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645

1. Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112 - DOI - PubMed - PMC

1. Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed

1. Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed

1. LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106 - DOI - PubMed - PMC

1. Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016 - DOI - PubMed

1. Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032 - DOI - PubMed

1. Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115

1. Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed

1. Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193 - DOI - PubMed - PMC

1. Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC

1. Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC

1. Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4 - DOI - PubMed


AST Structure:
-------------
├── DivNode
│   full_match: `{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}`
│   inner_content: `{maketoc Title=&quot;&quot;}`
│   attrs_dict:
│   │   raw_content: (class=&quot;lefth4&quot;)
│   │   class: lefth4
│   children:
│   ├── MakeTocNode
│   │   full_match: `{maketoc Title=&quot;&quot;}`
│   │   inner_content: ``
│   │   attrs_dict:
│   │   │   raw_content:  Title=&quot;&quot;
│   │   │   Title: ├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:`
│   inner_content: `Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:`
│   │   inner_content: `Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── BoldNode
│   full_match: `__ based on the National Health Claims Database 2017-2019__`
│   inner_content: ` based on the National Health Claims Database 2017-2019`
│   children:
│   ├── TextNode
│   │   full_match: `based on the National Health Claims Database 2017-2019`
│   │   inner_content: `based on the National Health Claims Database 2017-2019`├── TextNode
│   full_match: `\nOsteoporos Int  2024 Jan 19. `
│   inner_content: `\nOsteoporos Int  2024 Jan 19. `├── DoiLinkNode
│   full_match: `doi: 10.1007/s00198-024-07022-7`
│   inner_content: `10.1007/s00198-024-07022-7`├── TextNode
│   full_match: ` `
│   inner_content: ` `├── LinkNode
│   full_match: `[https://www.deepdyve.com/lp/springer-journals/selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-FCTILqFMaH?key=springer |Can be viewed at DeepDyve 1 month free trial]`
│   inner_content: `Can be viewed at DeepDyve 1 month free trial`
│   url: `https://www.deepdyve.com/lp/springer-journals/selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-FCTILqFMaH?key=springer `
│   children:
│   ├── TextNode
│   │   full_match: `Can be viewed at DeepDyve 1 month free trial`
│   │   inner_content: `Can be viewed at DeepDyve 1 month free trial`├── TextNode
│   full_match: `\nSeong-Eun Byun 1, Hasung Kim 2, Seung Yun Lee 2, Sang-Min Kim 3\n\n`
│   inner_content: `\nSeong-Eun Byun 1, Hasung Kim 2, Seung Yun Lee 2, Sang-Min Kim 3\n\n`├── FontNode
│   full_match: `{FONT(size=&quot;20&quot;)}__~~#00F:4X reduction in hip fractures in those who happened to be prescribed %%%to take some  amount of Vitamin D in addition to SERMS~~__{FONT}`
│   inner_content: `__~~#00F:4X reduction in hip fractures in those who happened to be prescribed %%%to take some  amount of Vitamin D in addition to SERMS~~__`
│   attrs_dict:
│   │   raw_content: size=&quot;20&quot;
│   │   size: 20
│   children:
│   ├── BoldNode
│   │   full_match: `__~~#00F:4X reduction in hip fractures in those who happened to be prescribed %%%to take some  amount of Vitamin D in addition to SERMS~~__`
│   │   inner_content: `~~#00F:4X reduction in hip fractures in those who happened to be prescribed %%%to take some  amount of Vitamin D in addition to SERMS~~`
│   │   children:
│   │   ├── ColorNode
│   │   │   full_match: `~~#00F:4X reduction in hip fractures in those who happened to be prescribed %%%to take some  amount of Vitamin D in addition to SERMS~~`
│   │   │   inner_content: `4X reduction in hip fractures in those who happened to be prescribed %%%to take some  amount of Vitamin D in addition to SERMS`
│   │   │   attrs_dict:
│   │   │   │   raw_content: #00F
│   │   │   children:
│   │   │   ├── TextNode
│   │   │   │   full_match: `4X reduction in hip fractures in those who happened to be prescribed `
│   │   │   │   inner_content: `4X reduction in hip fractures in those who happened to be prescribed `
│   │   │   ├── NewlineNode
│   │   │   │   full_match: `%%%`
│   │   │   │   inner_content: ``
│   │   │   ├── TextNode
│   │   │   │   full_match: `to take some  amount of Vitamin D in addition to SERMS`
│   │   │   │   inner_content: `to take some  amount of Vitamin D in addition to SERMS`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ImgNode
│   full_match: `{img type=&quot;attId&quot; attId=&quot;20688&quot; width=&quot;600&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  type=&quot;attId&quot; attId=&quot;20688&quot; width=&quot;600&quot;
│   │   type: attId
│   │   attId: 20688
│   │   width: 600├── TextNode
│   full_match: `\nWith the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.\n\nPurpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.\n\nMethods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.\n\nResults: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio `
│   inner_content: `\nWith the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.\n\nPurpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.\n\nMethods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.\n\nResults: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio `├── LinkNode
│   full_match: `[HR]`
│   inner_content: `HR`
│   url: `HR`
│   children:
│   ├── TextNode
│   │   full_match: `HR`
│   │   inner_content: `HR`├── TextNode
│   full_match: `, 0.77; 95% confidence interval `
│   inner_content: `, 0.77; 95% confidence interval `├── LinkNode
│   full_match: `[CI]`
│   inner_content: `CI`
│   url: `CI`
│   children:
│   ├── TextNode
│   │   full_match: `CI`
│   │   inner_content: `CI`├── TextNode
│   full_match: `, 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. \nAnalysis for specific fractures showed a `
│   inner_content: `, 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. \nAnalysis for specific fractures showed a `├── BoldNode
│   full_match: `__lower hazard of hip fracture in the SERM + VitD group (HR, 0.25__`
│   inner_content: `lower hazard of hip fracture in the SERM + VitD group (HR, 0.25`
│   children:
│   ├── TextNode
│   │   full_match: `lower hazard of hip fracture in the SERM + VitD group (HR, 0.25`
│   │   inner_content: `lower hazard of hip fracture in the SERM + VitD group (HR, 0.25`├── TextNode
│   full_match: `; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.\n\nConclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.\n`
│   inner_content: `; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.\n\nConclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.\n`├── HeadingNode
│   full_match: `\n!!!!!26 References`
│   inner_content: `26 References`
│   level: `5`
│   children:
│   ├── TextNode
│   │   full_match: `26 References`
│   │   inner_content: `26 References`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed`
│   inner_content: `Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed`
│   │   inner_content: `Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8 - DOI - PubMed - PMC`
│   inner_content: `Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8 - DOI - PubMed - PMC`
│   │   inner_content: `Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed`
│   inner_content: `Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed`
│   │   inner_content: `Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007 - DOI - PubMed - PMC`
│   inner_content: `Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007 - DOI - PubMed - PMC`
│   │   inner_content: `Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCO - DOI - PubMed - PMC`
│   inner_content: `Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCO - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCO - DOI - PubMed - PMC`
│   │   inner_content: `Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCO - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-x - DOI - PubMed`
│   inner_content: `Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-x - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-x - DOI - PubMed`
│   │   inner_content: `Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-x - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7 - DOI - PubMed - PMC`
│   inner_content: `Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7 - DOI - PubMed - PMC`
│   │   inner_content: `Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed`
│   inner_content: `Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed`
│   │   inner_content: `Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969`
│   inner_content: `Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969`
│   │   inner_content: `Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52`
│   inner_content: `Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52`
│   │   inner_content: `Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721 - DOI - PubMed`
│   inner_content: `Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721 - DOI - PubMed`
│   │   inner_content: `Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed`
│   inner_content: `Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed`
│   │   inner_content: `Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed`
│   inner_content: `Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed`
│   │   inner_content: `Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645`
│   inner_content: `Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645`
│   │   inner_content: `Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112 - DOI - PubMed - PMC`
│   inner_content: `Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112 - DOI - PubMed - PMC`
│   │   inner_content: `Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed`
│   inner_content: `Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed`
│   │   inner_content: `Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed`
│   inner_content: `Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed`
│   │   inner_content: `Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106 - DOI - PubMed - PMC`
│   inner_content: `LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106 - DOI - PubMed - PMC`
│   │   inner_content: `LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016 - DOI - PubMed`
│   inner_content: `Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016 - DOI - PubMed`
│   │   inner_content: `Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032 - DOI - PubMed`
│   inner_content: `Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032 - DOI - PubMed`
│   │   inner_content: `Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115`
│   inner_content: `Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115`
│   │   inner_content: `Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed`
│   inner_content: `Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed`
│   │   inner_content: `Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193 - DOI - PubMed - PMC`
│   inner_content: `Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193 - DOI - PubMed - PMC`
│   │   inner_content: `Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC`
│   inner_content: `Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC`
│   │   inner_content: `Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC`
│   inner_content: `Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC`
│   │   inner_content: `Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4 - DOI - PubMed`
│   inner_content: `Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4 - DOI - PubMed`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4 - DOI - PubMed`
│   │   inner_content: `Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4 - DOI - PubMed`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!! 76+ Hip fracture studies in VitaminDWiki `
│   inner_content: `76+ Hip fracture studies in VitaminDWiki`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `76+ Hip fracture studies in VitaminDWiki`
│   │   inner_content: `76+ Hip fracture studies in VitaminDWiki`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── EmphasisNode
│   full_match: `&#39;&#39;This list is automatically updated&#39;&#39;`
│   inner_content: `This list is automatically updated`
│   children:
│   ├── TextNode
│   │   full_match: `This list is automatically updated`
│   │   inner_content: `This list is automatically updated`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListNode
│   full_match: `{LIST()}\n{list max=&quot;150&quot;}\n{filter field=&quot;title&quot; content=&quot;\&quot;Hip Fracture\&quot; OR “\&quot;Hip Surgery\&quot; OR &quot;\&quot;Hip Replace\&quot;}\n{filter type=&quot;wiki page&quot;}\n{sort mode=&quot;modification_date_major_desc&quot;}\n{OUTPUT(template=&quot;table&quot;)}\n{tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}\n{column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}\n{column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}\n{OUTPUT}\n{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}\n{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}\n{LIST}`
│   inner_content: `\n{list max=&quot;150&quot;}\n{filter field=&quot;title&quot; content=&quot;\&quot;Hip Fracture\&quot; OR “\&quot;Hip Surgery\&quot; OR &quot;\&quot;Hip Replace\&quot;}\n{filter type=&quot;wiki page&quot;}\n{sort mode=&quot;modification_date_major_desc&quot;}\n{OUTPUT(template=&quot;table&quot;)}\n{tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}\n{column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}\n{column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}\n{OUTPUT}\n{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}\n{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}\n`
│   attrs_dict:
│   │   raw_content: 
│   children:
│   ├── TextNode
│   │   full_match: `\n{list max=&quot;150&quot;}\n{filter field=&quot;title&quot; content=&quot;\&quot;Hip Fracture\&quot; OR “\&quot;Hip Surgery\&quot; OR &quot;\&quot;Hip Replace\&quot;}\n{filter type=&quot;wiki page&quot;}\n{sort mode=&quot;modification_date_major_desc&quot;}\n{OUTPUT(template=&quot;table&quot;)}\n{tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}\n{column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}\n{column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}\n{OUTPUT}\n{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}\n{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}\n`
│   │   inner_content: `\n{list max=&quot;150&quot;}\n{filter field=&quot;title&quot; content=&quot;\&quot;Hip Fracture\&quot; OR “\&quot;Hip Surgery\&quot; OR &quot;\&quot;Hip Replace\&quot;}\n{filter type=&quot;wiki page&quot;}\n{sort mode=&quot;modification_date_major_desc&quot;}\n{OUTPUT(template=&quot;table&quot;)}\n{tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}\n{column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}\n{column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}\n{OUTPUT}\n{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}\n{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}\n`├── HorizontalRuleAltNode
│   full_match: `\n----\n`
│   inner_content: `----`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Falls and Fractures)) category`
│   inner_content: `VitaminDWiki – ((Falls and Fractures)) category`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Falls and Fractures))`
│   │   inner_content: `Falls and Fractures`
│   │   page: `Falls and Fractures`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Falls and Fractures`
│   │   │   inner_content: `Falls and Fractures`
│   ├── TextNode
│   │   full_match: ` category`
│   │   inner_content: ` category`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Falls and Fractures&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Falls and Fractures&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Falls and Fractures
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── TikiCommentNode
│   full_match: `~tc~ (alias(Hip fractor risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) ~/tc~`
│   inner_content: ` (alias(Hip fractor risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) `
│   children:
│   ├── TextNode
│   │   full_match: `(alias(Hip fractor risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) `
│   │   inner_content: `(alias(Hip fractor risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── TikiCommentNode
│   full_match: `~tc~ (alias(Hip fracture risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) ~/tc~`
│   inner_content: ` (alias(Hip fracture risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) `
│   children:
│   ├── TextNode
│   │   full_match: `(alias(Hip fracture risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) `
│   │   inner_content: `(alias(Hip fracture risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) `

Original Tiki:
-------------
{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}
---
!!!!Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:
__ based on the National Health Claims Database 2017-2019__
Osteoporos Int  2024 Jan 19. doi: 10.1007/s00198-024-07022-7 [https://www.deepdyve.com/lp/springer-journals/selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-FCTILqFMaH?key=springer |Can be viewed at DeepDyve 1 month free trial]
Seong-Eun Byun 1, Hasung Kim 2, Seung Yun Lee 2, Sang-Min Kim 3

{FONT(size=&quot;20&quot;)}__~~#00F:4X reduction in hip fractures in those who happened to be prescribed %%%to take some  amount of Vitamin D in addition to SERMS~~__{FONT}
{img type=&quot;attId&quot; attId=&quot;20688&quot; width=&quot;600&quot;}
With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.

Purpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.

Methods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.

Results: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. 
Analysis for specific fractures showed a __lower hazard of hip fracture in the SERM + VitD group (HR, 0.25__; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.

Conclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.

!!!!!26 References
#Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed
#Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8 - DOI - PubMed - PMC
#Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed
#Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007 - DOI - PubMed - PMC
#Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCO - DOI - PubMed - PMC
#Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-x - DOI - PubMed
#Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7 - DOI - PubMed - PMC
#Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed
#Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969
#Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52
#Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721 - DOI - PubMed
#Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed
#Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed
#Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645
#Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112 - DOI - PubMed - PMC
#Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed
#Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed
#LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106 - DOI - PubMed - PMC
#Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016 - DOI - PubMed
#Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032 - DOI - PubMed
#Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115
#Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed
#Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193 - DOI - PubMed - PMC
#Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC
#Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC
#Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4 - DOI - PubMed
---
!!!! 76+ Hip fracture studies in VitaminDWiki 
&#39;&#39;This list is automatically updated&#39;&#39;
{LIST()}
{list max=&quot;150&quot;}
{filter field=&quot;title&quot; content=&quot;\&quot;Hip Fracture\&quot; OR “\&quot;Hip Surgery\&quot; OR &quot;\&quot;Hip Replace\&quot;}
{filter type=&quot;wiki page&quot;}
{sort mode=&quot;modification_date_major_desc&quot;}
{OUTPUT(template=&quot;table&quot;)}
   {tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}
    {column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}
    {column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}
{OUTPUT}
{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}
{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}
{LIST}
----
!!!!VitaminDWiki – ((Falls and Fractures)) category
{include page=&quot;Falls and Fractures&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
~tc~ (alias(Hip fractor risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) ~/tc~
~tc~ (alias(Hip fracture risk reduced by 4X when Vitamin D was added to SERMS - Jan 2024)) ~/tc~
</code>
</pre></article></div></div><script src="/js/lightspa.js?v=1748177521"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1748177521",indexUrl:"/search/search_index.json.gz?v=1748177521"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/toc-sanitizer.js?v=1748177521"></script><script src="/js/search-results-panel.js?v=1748177521"></script><script src="/js/tiki-redirects.js?v=1748177521"></script></body></html>